Walleye Capital LLC Blueprint Medicines Corp Put Options Transaction History

Walleye Capital LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$84.1 - $120.5 $1.82 Million - $2.61 Million	-21,700 Reduced 64.97%	11,700 $1.08 Million
Q2 2024 Aug 14, 2024	BUY	$85.18 - $108.78 $1.82 Million - $2.33 Million	21,400 Added 178.33%	33,400 $3.6 Million
Q1 2024 May 15, 2024	BUY	$73.17 - $99.79 $878,040 - $1.2 Million	12,000 New	12,000 $1.14 Million
Q2 2023 Aug 14, 2023	SELL	$42.2 - $66.37 $295,400 - $464,590	-7,000 Reduced 81.4%	1,600 $101,000
Q1 2023 May 15, 2023	BUY	$37.97 - $50.0 $151,880 - $200,000	4,000 Added 86.96%	8,600 $386,000
Q4 2022 Feb 14, 2023	BUY	$41.06 - $66.48 $188,876 - $305,808	4,600 New	4,600 $201,000
Q1 2020 May 15, 2020	SELL	$48.11 - $82.22 $259,794 - $443,988	-5,400 Reduced 81.82%	1,200 $70,000
Q4 2019 Feb 14, 2020	BUY	$66.73 - $82.59 $440,418 - $545,094	6,600 New	6,600 $529,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.